Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 17/20 | 0.87 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.87 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.60 |
| ▸ | GRK5 | P34947 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.59 |
| ▸ | PRKX | P51817 | 1/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027737 | 0.93 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL5639896 | 0.93 | S1PR5 (0.76) | S1PR5S1PR1 | |
| SCHEMBL51920 | 0.93 | S1PR5 (0.81) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL3042076 | 0.90 | S1PR1 (0.77) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL2330642 | 0.87 | S1PR5 (0.68) | S1PR5S1PR1FUCA1 | |
| SCHEMBL30500506 | 0.87 | S1PR5 (0.72) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL1438433 | 0.87 | S1PR5 (0.72) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL3037437 | 0.86 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL250506 | 0.86 | S1PR5 (0.77) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL9037650 | 0.86 | S1PR5 (0.77) | S1PR5S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177783-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| US-20190175725-A1 | Prophylactic and Immunomodulatory Compositions and Uses | KHERION BIOTECH INC. | 2019-06-13 | — | — | US | claimed |
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| US-4812581-A | PREPARING AZETIDINE-3-CABOXYLIC ACID | SHELL OIL COMPANY (US) | 1989-03-14 | — | — | US | claimed |
| EP-0169602-B1 | PREPARATION OF N-SUBSTITUTED AZETIDINE 3-CARBOXYLIC ACID DERIVATIVES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-03-01 | — | — | EP | claimed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230233532-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST AND LIPOSOMAL FORMULATIONS THEREOF | THE PENN STATE RESEARCH FOUNDATION | 2023-07-27 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200317691-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-85104078-A | The preparation of 1-substituted azetidine-3-alcohol derivate | — | 1986-11-26 | — | — | CN | disclosed |
| EP-0199413-A2 | Process for preparing azetidine derivatives and novel intermediates therein | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-10-29 | — | — | EP | disclosed |
| EP-0169602-A1 | Preparation of n-substituted azetidine 3-carboxylic acid derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-01-29 | — | — | EP | disclosed |
| EP-0169603-A1 | Preparation of N-substituted-3-cyano azetidine derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-01-29 | — | — | EP | disclosed |
| EP-0168852-A1 | Azetidine derivatives and their preparation | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-01-22 | — | — | EP | disclosed |
| US-4560507-A | CYCLIZING N-BENZYL-3-AMINO-1-CHLOROPROPAN-2-OL AND TREATING THE RESULTING SALT WITH AN ALKALI METAL BASE | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0161722-A1 | Preparation of 1-substituted azetidine-3-ol derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-11-21 | — | — | EP | disclosed |
| EP-0125714-A1 | Preparation of 1-substituted azetidin-3-ol and acid halid thereof | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | S1PR5 2996/4885S1PR1 2157/4885S1PR3 2918/4885 |
| US-20200317691-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | S1PR5 1873/4885S1PR1 1988/4885S1PR3 1468/4885 |
| US-11053242-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | SLC18A2, SLC6A2, SLC18A1 | S1PR5 2602/4885S1PR1 2047/4885S1PR3 1987/4885 |
| US-20230233532-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST AND LIPOSOMAL FORMULATIONS THEREOF | S1PR1, S1PR2, S1PR3 | S1PR5 4/4885S1PR1 1/4885S1PR3 3/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | S1PR5 1873/4885S1PR1 1988/4885S1PR3 1468/4885 |
| US-20190175725-A1 | Prophylactic and Immunomodulatory Compositions and Uses | SPHK1, S1PR1, SPHK2 | S1PR5 8/4885S1PR1 2/4885S1PR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.